Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire's Lialda Launch For Ulcerative Colitis Will Focus On Dosing Convenience

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire is planning an sNDA for a remission maintenance claim within two years, the firm tells "The Pink Sheet" DAILY.

You may also be interested in...



Shire Ramps Up Lialda Sales Force Under TAP Agreement

Deal with Abbott/Takeda joint venture starts in April, quadruples number of reps on the drug.

Shire Ramps Up Lialda Sales Force Under TAP Agreement

Deal with Abbott/Takeda joint venture starts in April, quadruples number of reps on the drug.

Salix Expects Two NDA Submissions In Fourth Quarter For Gastrointestinal Indications

Firm’s granulated mesalamine is in development for ulcerative colitis, while its partner, Wilmington, plans to file metoclopramide-Zydis for gastroesphageal reflux.

Related Content

Topics

UsernamePublicRestriction

Register

PS065025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel